Novavax vaccine is set for the Launch of India: this is what you need to know; Efficacy & more

According to the NovaVax website, NVX-COV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-COV-2, a virus that causes Covid-19 disease. NVX-COV2373 is made using Novavax recombax nanoparticle technology to produce antigens originating from protein Coronavirus spike (s) and increasing medical care with a patented Saponin-M ™ Matrix-M ™ with Novavax with augmented immune response and stimulating high levels of neutralization antibodies.

Novavaks

American biotechnology companies, Novavax has produced a vaccine earlier for Ebola, influenza, virus syncytial respiratory (RSV), and other emerging infectious diseases. The company has a head office in Gaithersburg in the United States.

How efficient is the Novavax vaccine?

The initial data shows the vaccine is 90% effective and safe, according to the company. Side effects include headaches, fatigue, and muscle pain and generally mild.

Novavax Company.

Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company that promotes improved health globally through the invention, development and commercialization of innovative vaccines to prevent serious infectious diseases, stating the company’s official website. The exclusive recombinant technology platform company combines the strength and speed of genetic engineering to efficiently produce very immunogenic nanoparticles designed to handle urgent global health needs.

Indian Serum Institute to produce Novavaks

With the Indian Serum Institute, Novavax is ready to launch in India and the Jab vaccine can be expected in September 2021. According to a press release issued by Novavaks, the Serum Institute of India will produce ~ 1 billion doses of NVX-COV2373 this year. At present, Novavax named Covavax in India is at the continuation of the phase 2/3 trial. Meanwhile, SII has also signaled trials in children. India may be the first country to launch a vaccine. The trial was found effective against the Alfa variant which was first discovered in India with an efficiency of 86%.

On June 14, the company has announced, the Covid-19 vaccine has more than 93 percent of the efficacy of the mature virus virus circulating from attractive care and variants and offering 100 percent protection against moderate and severe diseases. The government has accommodated 20 doses of Covovax Crore for India for the expected inoculation drive between September and December. To evaluate efficiency, Novavax studies are registered with 29,960 participants in 119 sites in the US and Mexico.